【PharmaEssentia】Company's New Drug BESREMi (Ropeginterferon alfa-2b) Receives Approval Letter from Ministry of Health and Welfare for Use in Essential Thrombocythemia (ET)
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
PharmaEssentia's new drug BESREMi has received approval from Taiwan's Ministry of Health and Welfare for an expanded indication to treat adult patients with essential thrombocythemia (ET) who are resistant or intolerant to hydroxyurea treatment. This approval expands treatment options for patients and positions the company to pursue National Health Insurance (NHI) coverage and accelerate sales and marketing efforts.